Compare EBS & BDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EBS | BDN |
|---|---|---|
| Founded | 1998 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.9M | 528.1M |
| IPO Year | 2006 | 1995 |
| Metric | EBS | BDN |
|---|---|---|
| Price | $8.10 | $2.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $3.50 |
| AVG Volume (30 Days) | 614.2K | ★ 1.9M |
| Earning Date | 04-30-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 10.67% |
| EPS Growth | ★ 125.83 | 9.65 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $742,900,000.00 | $484,454,000.00 |
| Revenue This Year | $1.29 | $12.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $116.79 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.62 | $2.47 |
| 52 Week High | $14.06 | $4.63 |
| Indicator | EBS | BDN |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 48.00 |
| Support Level | $7.73 | $2.91 |
| Resistance Level | $8.95 | $3.15 |
| Average True Range (ATR) | 0.55 | 0.09 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 27.17 | 13.46 |
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.